Janus Henderson Group PLC Decreases Stock Position in Savara Inc (NASDAQ:SVRA)

Janus Henderson Group PLC lessened its stake in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 89.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 245,800 shares of the company's stock after selling 2,030,660 shares during the period. Janus Henderson Group PLC owned about 0.14% of Savara worth $1,041,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. lifted its position in shares of Savara by 103.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company's stock valued at $32,874,000 after buying an additional 4,157,385 shares during the last quarter. Vestal Point Capital LP lifted its holdings in Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company's stock valued at $34,302,000 after purchasing an additional 1,600,000 shares during the last quarter. Jennison Associates LLC boosted its position in Savara by 17.5% during the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company's stock worth $28,547,000 after purchasing an additional 1,001,296 shares during the period. Nantahala Capital Management LLC increased its stake in shares of Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company's stock worth $20,879,000 after purchasing an additional 3,443,541 shares in the last quarter. Finally, Farallon Capital Management LLC raised its position in shares of Savara by 90.5% in the second quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company's stock valued at $18,377,000 after purchasing an additional 2,165,701 shares during the period. Institutional investors own 87.93% of the company's stock.

Savara Price Performance

NASDAQ:SVRA traded down $0.14 during trading hours on Friday, hitting $3.21. The stock had a trading volume of 3,170,820 shares, compared to its average volume of 1,278,070. The firm has a market capitalization of $550.90 million, a price-to-earnings ratio of -7.47 and a beta of 0.92. Savara Inc has a one year low of $2.82 and a one year high of $5.70. The company has a 50 day simple moving average of $3.52 and a two-hundred day simple moving average of $4.02. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting analysts' consensus estimates of ($0.11). Research analysts forecast that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SVRA has been the subject of several analyst reports. HC Wainwright cut their price objective on shares of Savara from $10.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. Evercore ISI reaffirmed an "in-line" rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, JMP Securities reiterated a "market outperform" rating and set a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Savara currently has an average rating of "Moderate Buy" and a consensus price target of $10.17.

Insiders Place Their Bets

In related news, Director Joseph S. Mccracken bought 20,000 shares of the stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $2.95 per share, with a total value of $59,000.00. Following the purchase, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. The trade was a 10.48 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 5.13% of the company's stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.